Status:
NOT_YET_RECRUITING
Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy
Lead Sponsor:
University of Modena and Reggio Emilia
Collaborating Sponsors:
Azienda USL Reggio Emilia - IRCCS
Conditions:
Stem Cell Transplantation
Immunotherapy
Eligibility:
All Genders
18+ years
Brief Summary
Hematopoietic Stem Cell Transplantation (HSCT) and CAR T-cell therapy are effective treatments for blood cancers, extending patients lives. However, these treatments can cause side effects like muscle...
Detailed Description
This is a prospective observational study following STROBE guidelines for observational studies in epidemiology. The study will take place at the Azienda USL-IRCCS di Reggio Emilia, Northern Italy. P...
Eligibility Criteria
Inclusion
- Patients with hematologic cancer scheduled to undergo HSCT or CAR T-cell therapy;
- Age ≥18 years
- Able to provide informed consent to participate in the study
- Able to understand and participate in the study
- Able to understand and communicate in the Italian language
Exclusion
- • Patients who are unable to perform physical tests or have contraindications to movement
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06506396
Start Date
August 1 2024
End Date
May 1 2025
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AUSL-IRCCS di Reggio Emilia
Reggio Emilia, Italy, 42122